Pohlreich and co-workers report a decreased incidence and severity of acute gastrointestinal toxicity when substituting Methotrexate (MTX) with Mycofenolate Mofetil (MMF) for the prevention of graft-versus-host disease in stem cell transplantation following myeloablative conditioning. They do not find a significant difference in time to engraftment between patient groups. In our study, we concluded that the toxicity profile of Cyclosporine A (CSA)/MMF in comparison to CSA/ MTX is superior as mainly reflected by the shorter time to engraftment. 1 Owing to the fact that we referred to retrospective data, we did not report in detail the severity of mucositis among patients treated at our center. Documentation was not standardized and supportive care improved during the study period, making a direct comparison difficult. However, we also observed a decreased incidence of severe mucositis and length of hospitalization, which can be interpreted as a consequence of the substitution of MMF for MTX. In addition to a favorable gastrointestinal toxicity profile, the accelerated engraftment, which is associated with the resolution of mucositis in most cases, may be responsible for these differences.
With respect to engraftment, Pohlreich and co-workers did not find a significant difference between patients receiving CSA/MMF or CSA/MTX. This may be explained by several details of their data. The relatively small patient groups included heterogeneous patient populations with respect to age, diagnosis, donor type and probably disease stage and transplant source. First, the main patient group receiving CSA/MTX had chronic myelogenous leukemia (65%) whereas this group represented only 38% in the CSA/MMF group. Second, HLA-identical sibling transplants were mixed with MUD transplants favoring the CSA/MTX group. It is very likely that the proportions of peripheral blood stem cells (PBSCs) and bone marrow are not equally balanced which may lead to a longer time to hematopoietic reconstitution in the group including more marrow transplants. Moreover, numbers of transplanted CD34 þ cells may be different between groups as well as the number of previous therapies.
To avoid this bias, we focused our analysis on welldefined patient groups and looked only at patients with leukemia receiving transplants from HLA-identical siblings in early disease stages. A shorter time to hematopoietic reconstitution was evident, even if only patients receiving mobilized PBSCs were analyzed. This is in line with the data of Bolwell et al.
2 who reported similar results from a Reply well designed randomized trial in patients receiving marrow from HLA-identical siblings. Patients receiving CSA/MMF had significant faster engraftment (11 days) than did patients receiving CSA/MTX (18 days). In addition, Nash et al. 3 recently reported a time to hematopoietic reconstitution of 15 days using CSA/MMF after transplantation of PBSCs from HLA-identical siblings following myeloablative conditioning. To explain the relatively long time to neutrophil reconstitution (22 days) with certainty in patients receiving CSA/MMF reported by Pohreich et al., more details on patient and treatment characteristics are needed.
In conclusion, we suggest that the substitution of MTX by MMF is a feasible approach to reducing organ toxicity, namely mucositis and achieving earlier engraftment. We support the view that reducing toxicity is a major goal in stem cell transplantation in terms of patient safety and reduction of costs. As the influence of different diagnoses, conditioning regimens and stem cell sources on factors such as organ toxicity, time to hematopoietic reconstitution, GvHD incidence and relapse are well known problems with retrospective analysis, prospective studies in homogeneous patient groups are needed.
